Navigation Links
New model may help predict response to chemotherapy for colorectal cancer
Date:1/16/2013

PHILADELPHIA Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, a journal of the American Association for Cancer Research.

"Our study demonstrates that systems medicine approaches (i.e., quantitative analysis of multiple factors in patients' samples combined with mathematical modeling) have a significant advantage over other approaches in predicting therapy responses in patients," said Jochen J.M. Prehn, Ph.D., director of the Centre for Systems Medicine at the Royal College of Surgeons in Ireland.

Apoptosis, or programmed cell death, is believed to be a hallmark of cancer resistance to chemotherapy. Prior research has shown that the key step in apoptosis, the process that leads to mitochondrial outer membrane permeabilization (MOMP) is controlled by different members of the BCL-2 family of proteins. Some family members promote apoptosis and some prevent it. In addition, those proteins that have the same effects on apoptosis work in parallel and can substitute for each other, which makes it difficult to predict whether cells are likely or unlikely to die.

To better inform decision-making in chemotherapy for colorectal cancer, Prehn and colleagues developed a tool that would incorporate patient-specific, molecular data sets. They studied the BCL-2 proteins, determined levels of the individual proteins and put the levels into a mathematical model that calculated what genotoxic stress level is needed to achieve apoptosis.

"Resistance of colon cancer cells in culture, as well as treatment responses of patients with stages 2 and 3 colon cancer, were critically determined by the calculated stress level required to undergo apoptosis," Prehn said. "We found that individual patients had a high degree of heterogeneity in BCL-2 family protein levels and that this was a potential cause of the success or failure of adjuvant chemotherapy."

Prehn and colleagues tested a clinical decision-making tool that they call DR_MOMP to determine its use in predicting treatment responses in patients with colon cancer. Using DR_MOMP, they were able to robustly predict patient outcome.

"This finding may provide a clinical decision-making tool that enables predictions of treatment responses in patients with colon cancer," Prehn said. "As we provide a quantitative, dynamic analysis of the process of apoptosis, we can also calculate, for individual patients, the therapeutic window."

The model could help predict how much genotoxic stress is required for a cancer cell to die before normal tissue is affected. Prehn and colleagues hope to validate DR_MOMP in other cancers and in larger patient cohorts.

"We need to develop easy and accessible protein profiling and modeling platforms that enable the implementation of this new technology in clinical trials and in pathology laboratories," Prehn said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. UK-Based Laminin Solutions and NLP Logix Formalize Agreement to Leverage the Power and Flexibility of M-Files with Big Data Predictive Modeling
2. Just what the doctor ordered for the New Year- New Talent with Nancy Di Nino’s BRAVADO, Branding, Marketing & Management Services for athletes & models
3. New Model [ZT-F1012-31221A] T10 Tube has been Added to Zhongtian Lighting’s Production Line
4. American Crane's Website Now Includes 3D Models!
5. New rat model for muscle regeneration after trauma-related soft tissue injury
6. NLP Logix Signed to Provide Predictive Modeling Services for Worker Compensation Physical Therapy Provider
7. Supportive role models, coping lead to better health in poor teens
8. Researchers find model system to study promising cancer drug
9. Predicting risk of arrhythmias and sudden cardiac death: Theres a computer model for that
10. New hormone therapy shows promise for menopausal symptoms in animal model
11. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers announced today that it ... center will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye ... full-service facility to ensure that patients continue to receive the highest quality of care. ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people are ... reach out via email, social media and on the Volonté blog seeking advice about ... I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than others, ...
(Date:5/5/2016)... Collins, CO (PRWEB) , ... May 05, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:5/5/2016)... Houston, TX (PRWEB) , ... May 05, 2016 , ... ... 2015 AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the ... and designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October ...
(Date:5/5/2016)... ARIZ. (PRWEB) , ... May 05, 2016 , ... ... president Jennifer Drago presented a talk highlighting the organization’s successful Care Transitions ... in Chicago. , The talk was titled “Minimizing Costs in the Post-Acute Environment ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... with watching a film or TV show in high definition, you may not be familiar ... Ampronix  is a renowned authorized reseller of the medical industry,s top brands as well as ... ... ... Although initially ...
(Date:5/3/2016)... DUBLIN , May 3, 2016 ... to pay $55 million to a woman who says ... State court awarded Gloria Ristesund $5 million ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... of accusations against the company. In February, the same ...
(Date:5/3/2016)... JERUSALEM , May 3, 2016 ... (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the ... Clinical and Regulatory Affairs. "Ms. Strauss-Levy has ... affairs, and has established an outstanding track record, having ... development and regulatory approval processes in the ...
Breaking Medicine Technology: